The MIER2 Knockout Raji Polyclonal Cells are a CRISPR/Cas9-mediated gene disruption model, generating a polyclonal population of Raji B lymphoblasts with targeted inactivation of the MIER2 locus. This product offers a heterogeneous knockout cell pool suitable for functional studies of MIER2-mediated transcriptional repression.
Raji cells are a well-characterized B lymphoblast line, originally derived from a Burkitt lymphoma patient and immortalized by Epstein-Barr virus. They serve as a widely used model for B-cell malignancies, antibody production, and immune response studies. The lymphoblastoid nature of Raji cells provides a physiologically relevant context for examining oncogenic transcriptional programs, particularly those driven by aberrant repressor activities. This knockout cell population enables dissection of MIER2’s role within the chromatin landscape of a B-cell lymphoma background.
MIER2 functions as a transcriptional repressor that orchestrates gene silencing by tethering histone deacetylase complexes to target gene promoters. It directly interacts with HDAC1, HDAC2, and the corepressor SIN3A, and is known to associate with ER-alpha. Through these interactions, MIER2 facilitates chromatin condensation, thereby repressing transcription of genes involved in cell proliferation and apoptosis. The activity of MIER2 is regulated by upstream signals including NF-??B and estrogen receptors, and its repression targets intersect with TGF-beta signaling. In the broader transcriptional repression machinery, MIER2 operates alongside components such as NCOR1 and SMRT. Disruption of MIER2 likely alleviates this repression, leading to derepression of genes that control cell growth and survival, making this knockout model valuable for dissecting epigenetic mechanisms.
In Raji B lymphoblasts, dysregulation of transcriptional repression contributes to the malignant phenotype, and MIER2 knockout offers a platform to examine how loss of this repressor alters gene expression programs central to lymphomagenesis. By removing MIER2-mediated silencing, researchers can study the resulting changes in pathways governing cell cycle, apoptosis, and differentiation in a cell line that inherently models Burkitt lymphoma. This system is particularly relevant for exploring the interplay between epigenetic silencing and oncogenic signaling in B-cell malignancies and for identifying potential vulnerabilities arising from repressor loss.
The MIER2 Knockout Raji Polyclonal Cells are suitable for a wide range of functional genomics and drug discovery applications, including RNA-seq and ChIP-qPCR to assess transcriptomic and epigenomic changes, western blotting and RT-qPCR for target gene validation, and cell-based assays such as proliferation, apoptosis, and flow cytometry to evaluate phenotypic consequences. These cells support investigations into transcriptional regulation, epigenetic mechanisms, and signaling networks in B-cell lymphoma, and can be employed for target validation in breast and lung adenocarcinoma contexts where MIER2 involvement has been implicated. For additional technical details or inquiries, please contact Ascent Research.
